


Actual or anticipated 4 units RBC in < 4 hours, + haemodynamically unstable, +/- anticipated ongoing bleeding Severe thoracic, abdominal, pelvic or multiple long bone trauma, major gastrointestinal, surgical or obstetric bleeding

Senior clinician determines that patient meets criteria for MASSIVE TRANSFUSION PROTOCOL activation



SCGH Massive Transfusion Protocol and ROTEM algorithm for critical bleeding endorsed by the SCGH blood transfusion committee April 2017, page 1 of 3





Refer to **The SCGH ROTEM** Algorithm

for Critical bleeding

for the blood product dosing guide Page 2 of 3

Special Clinical

Indications Warfarin, antiplatelet and novel oral anticoagulants (NOACS)


Refer to page 3 of 3 for further information

SCGH ROTEM Algorithm for Critical Bleeding

Key Points: This algorithm is for use in patients with CRITICAL BLEEDING only. Only treat abnormal values if active bleeding or at high risk of bleeding. Repeat ROTEM analysis 10 mins after intervention to assess response.

| | ABNORMAL ROTEM | CRITERIA | | DIAGNOSIS | INTERVENTION | CORRECTED ROTEM | |
|--------------|---|---|---|--------------------------------------|---|--|--|
| FIBRINOLYSIS | EXTEMS ST: 112246 RT: 010254 CT: 149 5 CFT: 246 5 A 5 31 mm ML: 100 % ML: 100 % A20: 4 mm | Early Diagnosis EXTEM A5≤35mm or FIBTEM CT >600s | | h likelihood of ess fibrinolysis | Tranexamic acid 1g Consider repeat dose if has lost over 1 blood volume | EXTEM'S 51: 02:51:07 81: 01:27:28 CT: 52:s CFT: 104:s A 5 60 mm MCF: 67 mm | |
| | | Late Diagnosis EXTEM or FIBTEM ML ≥5% | Exc | ess fibrinolysis | since initial dose (If no contra-indications) | e ML: * % e Gr. 70 * 18 29 29 69 39 etc. | |
| FIBRINOGEN | FIBTEM'S ST:220928 RT:0:3016 CT: 45 CT: A5: MCP: MCP: MC: ST:220928 MC: ST:20928 MC: ST:20928 MC: ST:20928 MC: ST:20928 MC: ST:20928 | FIBTEM A5≤10mm | L | ow fibrinogen | Cryoprecipitate (see dosing guide) | FIBTEM'S ST: 023957 CT: 53 5 CT: 53 5 CFI: A 5 17 mm MCF: 18 mm MCF: 18 mm A20: 18 mm | |
| PLATELETS | EXTEMS 51: 220835 RT: 01:3018 RT: 01:3018 | EXTEM A5 ≤35mm and FIBTEM A5 >10mm | L | ow platelets. | Platelets: 1 adult dose (correlate with platelet count) | EXTEM'S ST: 025107 RT: 012728 CT: 52 s CFT: 104 s A5: 60 mm | |
| | | EXTEM A5 ≤25mm and FIBTEM A5 ≤10mm | | .ow platelets Low fibrinogen | Platelets and fibrinogen (correlate with platelet count) | MCF: 67 mm ML: * % a a 3 a 4 5 70 * A20: 67 mm 18 28 28 48 58 ent | |
| ACTORS | EXTEMS Tr. 011726 Tr. 210 s Tr. 422 A 5: 24 mm MCF: 38 mm MCF: 38 mm ML: * 5 % a: 46 * A20: 33 mm | EXTEM CT 80-140s and FIBTEM A5 ≤10mm | | | Correct fibrinogen and reassess | EXTEM'S 51: 0251.07 81: 012728 CT: 52 1 CT: 52 1 | |
| | | EXTEM CT >80s but FIBTEM A5 >10mm | Low co | oagulation factors | FFP 1-4U or | A 5 : 60 mm A 5 : 60 mm MCF: 67 mm ML: * % C 70 * A 20: 67 mm | |
| E | | EXTEM CT >140s and FIBTEM A5 ≤10mm | | fibrinogen and pagulation factors | (+ Fibrinogen if indicated) | | |
| | Fibrinogen Dosing Guide | | | | | | |
| | FIBTEM A5 Cryoprecipi- | | | mplitude (n | | ML | |
| | 9-10mm | 2-3 mm 10 Ur | - | | A5 | | |
| | 7-8mm | 4-5 mm 15 Ur | | | | | |
| | 4-6mm | 6-8 mm 20 Ur | | | | | |
| | | ≥9mm 20-25 U ryoprecipitate dosing is for standard adult units yo 5 units = Fibtem A5 increase of approx 2mm) | cipitate dosing is for standard adult units | | 10 15 20 | Time (minutes) | |

Endorsed by the SCGH Blood Transfusion Committee, Departments of Anaesthesia, Pain Medicine & Haematology January 2017 Adapted from KEMH hospital algorithm with permission page 2 of 3



PATIENTS ON ANTICOAGULANTS EXPERIENCING CRITICAL BLEEDING - QUICK REFERENCE GUIDE

**FOR GENERAL REFERENCE ONLY - DISCUSS ALL MANAGEMENT WITH HAEMATOLOGIST

Patients on anticoagulants have an underlying predisposition to thrombosis and the decision to use pharmacologic reversal should always be balanced against the risk of precipitating thrombosis. Where feasible maximise the use of non - pharmacologic treatments such as surgical techniques, embolisation or balloon tamponade / packing. Seek advice from the appropriate specialists and Haematology. In critical or life threatening haemorrhage urgent reversal may still be required: (see below)

Detect and Exclude other abnormalities Perform ROTEM to detect and treat other abnormalities that may develop during haemorrhage e.g. low fibrinogen or platelets, hyperfibrinolysis, coagulation factor deficiency.

| | DIAGNOSTIC TESTS | INTERVENTION & REVERSAL | | |
|--|--|--|--|--|
| WARFARIN | | uide reversal insensitive) | Vitamin K 5-10mg IV Prothrombinex VF 25 - 50 U/kg +/- FFP 1-2 units | |
| HEPARIN (Unfractionated) | INTEM CT > 240s and HEPTEM CT / INTEM CT > 0.8 (- indicates reversible heparin effect) APTT > 38s | | Cease heparin (short half life) Consider protamine 1mg / 100u heparin Give protamine slowly 10mg/min -Maximum dose 50mg | |
| LMWH (low molecular weight heparin)" | INTEM CT > 240s Anti Factor Xa Levels | | Up to 60% of LMWH effect may be reversible with protamine | Consider Protamine (max 50mg): If < 8hrs: Protamine 1mg / 1mg enoxaparin If > 8hrs: Protamine 0.5mg / 1mg enoxaparin - Give protamine slowly 10mg/min |
| NOACS (Novel Oral Anticoagulants) | AGENT - Mechanism of action Dabigatran - Direct thrombin inhibitor Rivaroxaban - Direct Xa inhibitor Apixaban - Direct Xa inhibitor | Laboratory Tests / Antidotes Dabigatran level/ Idarucizumab click here Rivaroxaban/ Apixaban level No Antidote Available | General Advice Maximise physical measures: Direct pressure Embolisation Surgical ligation | Pro-Haemostatic Drugs (if no antidote) Discuss with on call Haematologist In life-threatening bleeding when other measures have failed consider: Prothrombinex VF 25-50iu/kg Tranexamic Acid 1g |
| Anti-p | latelets agents (Aspirin & Clopid | Give one adult dose of platelets | | |

Endorsed by the SCGH Blood Transfusion Committee, Departments of Anaesthesia, Pain Medicine & Haematology January 2017 Adapted from KEMH hospital algorithm with permission page 3 of 3